| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel
Tumor-associated mutants of the p53 tumor suppressor protein exert biological activities compatible with an oncogenic gain of function. To explore the underlying molecular mechanism, we performed microarray analysis, comparing p53-null cells to mutant p53-expressing cells. One of the genes up-regulated in the presence of mutant p53 was EGR1, a transcription factor implicated in growth control, apoptosis, and cancer. EGR1 induction by various types of stress is markedly augmented in cells expressing mutant p53. Moreover, chromatin immunoprecipitation analysis indicates that mutant p53 is physically associated with the EGR1 promoter. Functional assays indicate that induction of EGR1 by mutant p53 contributes to enhanced transformed properties and resistance to apoptosis. We propose that EGR1 is a significant contributor to mutant p53 gain of function.
This article has been cited by other articles:
![]() |
T.-H. Kim, S. Y. Lee, J. H. Rho, N. Y. Jeong, Y. H. Soung, W. S. Jo, D.-Y. Kang, S.-H. Kim, and Y. H. Yoo Mutant p53 (G199V) Gains Antiapoptotic Function through Signal Transducer and Activator of Transcription 3 in Anaplastic Thyroid Cancer Cells Mol. Cancer Res., October 1, 2009; 7(10): 1645 - 1654. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Tu, A. L. Chi, W. Ai, S. Takaishi, Z. Dubeykovskaya, M. Quante, J. G. Fox, and T. C. Wang p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells Am J Physiol Gastrointest Liver Physiol, August 1, 2009; 297(2): G385 - G396. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sur, R. Pagliarini, F. Bunz, C. Rago, L. A. Diaz Jr., K. W. Kinzler, B. Vogelstein, and N. Papadopoulos A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 PNAS, March 10, 2009; 106(10): 3964 - 3969. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Bassett, W. Wang, F. Rastinejad, and W. S. El-Deiry Structural and Functional Basis for Therapeutic Modulation of p53 Signaling Clin. Cancer Res., October 15, 2008; 14(20): 6376 - 6386. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Guida, A. Bisso, C. Fenollar-Ferrer, M. Napoli, C. Anselmi, J. E. Girardini, P. Carloni, and G. Del Sal Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells Cancer Res., August 15, 2008; 68(16): 6550 - 6558. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kalo, Y. Buganim, K. E. Shapira, H. Besserglick, N. Goldfinger, L. Weisz, P. Stambolsky, Y. I. Henis, and V. Rotter Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor {beta}1 (TGF-{beta}1) Signaling Pathway by Repressing the Expression of TGF-{beta} Receptor Type II Mol. Cell. Biol., December 1, 2007; 27(23): 8228 - 8242. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Weisz, A. Damalas, M. Liontos, P. Karakaidos, G. Fontemaggi, R. Maor-Aloni, M. Kalis, M. Levrero, S. Strano, V. G. Gorgoulis, et al. Mutant p53 Enhances Nuclear Factor {kappa}B Activation by Tumor Necrosis Factor {alpha} in Cancer Cells Cancer Res., March 15, 2007; 67(6): 2396 - 2401. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. C. Wong, W. P. Tsang, P. Y. Chau, N. N. Co, T. Y. Tsang, and T. T. Kwok p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3 Mol. Cancer Ther., March 1, 2007; 6(3): 1054 - 1061. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Buganim, E. Kalo, R. Brosh, H. Besserglick, I. Nachmany, Y. Rais, P. Stambolsky, X. Tang, M. Milyavsky, I. Shats, et al. Mutant p53 Protects Cells from 12-O-Tetradecanoylphorbol-13-Acetate-Induced Death by Attenuating Activating Transcription Factor 3 Induction. Cancer Res., November 15, 2006; 66(22): 10750 - 10759. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mizuarai, K. Yamanaka, and H. Kotani Mutant p53 Induces the GEF-H1 Oncogene, a Guanine Nucleotide Exchange Factor-H1 for RhoA, Resulting in Accelerated Cell Proliferation in Tumor Cells. Cancer Res., June 15, 2006; 66(12): 6319 - 6326. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Scian, K. E. R. Stagliano, M. A. E. Anderson, S. Hassan, M. Bowman, M. F. Miles, S. P. Deb, and S. Deb Tumor-Derived p53 Mutants Induce NF-{kappa}B2 Gene Expression Mol. Cell. Biol., November 15, 2005; 25(22): 10097 - 10110. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Worden, X. P. Yang, T. L. Lee, L. Bagain, N. T. Yeh, J. G. Cohen, C. Van Waes, and Z. Chen Hepatocyte Growth Factor/Scatter Factor Differentially Regulates Expression of Proangiogenic Factors through Egr-1 in Head and Neck Squamous Cell Carcinoma Cancer Res., August 15, 2005; 65(16): 7071 - 7080. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |